 MiMedx Group, Inc. OTC PINK: MDXG MiMedx or the Company, an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the closing of concurrent 150 million private equity and debt financings, consisting of an equity financing pursuant to a Securities Purchase Agreement with an entity controlled by EW Healthcare Partners and certain funds managed by Hayfin Capital Management LLP Hayfin, and a debt financing pursuant to a Loan Agreement with Hayfin. As part of the transaction, EW Healthcare Partners has designated Martin P. Sutter and William A. Hawkins III to serve on the Companys board as preferred directors. 